These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9595977)

  • 1. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis.
    Rudick RA; Ransohoff RM; Lee JC; Peppler R; Yu M; Mathisen PM; Tuohy VK
    Neurology; 1998 May; 50(5):1294-300. PubMed ID: 9595977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
    Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
    J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
    J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of interferon beta-1a in multiple sclerosis.
    Liu Z; Pelfrey CM; Cotleur A; Lee JC; Rudick RA
    J Neuroimmunol; 2001 Jan; 112(1-2):153-62. PubMed ID: 11108944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis.
    Rajendran R; Rajendran V; Gupta L; Shirvanchi K; Schunin D; Karnati S; Giraldo-Velásquez M; Berghoff M
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
    Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis.
    Yu M; Nishiyama A; Trapp BD; Tuohy VK
    J Neuroimmunol; 1996 Jan; 64(1):91-100. PubMed ID: 8598395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Rebif new formulation story: it's not trials and error.
    Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
    Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
    Khan OA; Xia Q; Bever CT; Johnson KP; Panitch HS; Dhib-Jalbut SS
    Neurology; 1996 Jun; 46(6):1639-43. PubMed ID: 8649563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis.
    Martín-Saavedra FM; Flores N; Dorado B; Eguiluz C; Bravo B; García-Merino A; Ballester S
    Mol Immunol; 2007 Jul; 44(14):3597-607. PubMed ID: 17420051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Sep; 51(3):738-42. PubMed ID: 9748019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.